ClearFlow, a California-based medical device company specializing in creating products to solve issues related to obstructed catheters, has entered into an agreement with Mayo Clinic in Rochester, Minn., to conduct research to improve care quality for patients recovering from heart surgery.
"Recent studies have demonstrated that up to 20 percent of patients recovering from heart surgery have some form of intervention due to retained blood that can slow recovery and increase the costs of care," said Edward Boyle, MD, co-founder and chairman of ClearFlow. "The goal of this study is to implement structured protocols in the ICU that can facilitate improved recovery for patients after heart surgery."
The study will implement the use PlueraFlow ACT, a device created by ClearFlow to prevent chest tubes from clogging in the first 24 to 48 hours after heart surgery.
Paul Molloy, ClearFlow CEO, said, "It's an honor to work with Mayo Clinic on this research — an organization known worldwide for its commitment to continuous quality improvement to optimize patient care."